" class="no-js "lang="en-US"> Samsung Biologics Archives - Medtech Alert
Friday, March 29, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Samsung Biologics Reaches Agreement with Biogen to Acquire Full Ownership of Samsung Bioepis

Samsung Biologics (KRX: 207940.KS) announced today that it has reached an agreement with Biogen for the buyout […]

GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing

GreenLight Biosciences (Nasdaq: ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and […]

Samsung Biologics to Add mRNA Vaccine Drug Substance Manufacturing Suite to Expand Portfolio of Services

Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing end-to-end contract development and manufacturing services, […]

Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab

Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and manufacturing organization and TG Therapeutics […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more